* patients who at the time of admission require hospitalization and / or supplemental oxygen. * known history of allergy to ivermectin. * known medical history of liver disease. * belong to another clinical trial evaluating the efficacy of an investigational drug against covid-19. * the following comorbidities: * immunosuppression or hiv. * acute or chronic kidney failure. * current neoplasia. * currently use of warfarin, erdafitinib, or quinidine. * have received vaccination for sars-cov-2. * ivermectin consumption prior to inclusion in the research protocol. * the patient does not accept the conditions of home care and monitoring. * the patient desists from participating in the study. * women in pregnancy or breastfeeding.

* patients who at the time of admission require hospitalization and / or supplemental oxygen. * known history of allergy to ivermectin. * known medical history of liver disease. * belong to another clinical trial evaluating the efficacy of an investigational drug against covid-19. * the following comorbidities: * immunosuppression or hiv. * acute or chronic kidney failure. * current neoplasia. * currently use of warfarin, erdafitinib, or quinidine. * have received vaccination for sars-cov-2. * ivermectin consumption prior to inclusion in the research protocol. * the patient does not accept the conditions of home care and monitoring. * the patient desists from participating in the study. * women in pregnancy or breastfeeding.

- patients who at the time of admission require hospitalization and / or supplemental oxygen. - known history of allergy to ivermectin. - known medical history of liver disease. - belong to another clinical trial evaluating the efficacy of an investigational drug against covid-19. - the following comorbidities: - immunosuppression or hiv. - acute or chronic kidney failure. - current neoplasia. - currently use of warfarin, erdafitinib, or quinidine. - have received vaccination for sars-cov-2. - ivermectin consumption prior to inclusion in the research protocol. - the patient does not accept the conditions of home care and monitoring. - the patient desists from participating in the study. - women in pregnancy or breastfeeding.

- patients who at the time of admission require hospitalization and / or supplemental oxygen. - known history of allergy to ivermectin. - known medical history of liver disease. - belong to another clinical trial evaluating the efficacy of an investigational drug against covid-19. - the following comorbidities: - immunosuppression or hiv. - acute or chronic kidney failure. - current neoplasia. - currently use of warfarin, erdafitinib, or quinidine. - have received vaccination for sars-cov-2. - ivermectin consumption prior to inclusion in the research protocol. - the patient does not accept the conditions of home care and monitoring. - the patient desists from participating in the study. - women in pregnancy or breastfeeding.